诊断前 IgE 水平与胶质瘤风险的关联。
Association between prediagnostic IgE levels and risk of glioma.
机构信息
Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH 43210, USA.
出版信息
J Natl Cancer Inst. 2012 Aug 22;104(16):1251-9. doi: 10.1093/jnci/djs315. Epub 2012 Aug 1.
BACKGROUND
Previous nested case-control studies suggest that a prediagnostic biomarker of allergy, IgE, is inversely associated with the risk of glioma, but these findings are inconsistent. The purpose of our study was to assess this association and determine how long before glioma diagnosis it may be observed.
METHODS
We conducted a nested case-control study using serum specimens from the Janus Serum Bank cohort in Norway. Blood donors who were subsequently diagnosed with glioma (n = 594 case subjects), between January 1, 1974 to December 31, 2007, were matched with subjects without glioma (n = 1177 control subjects) for date of blood collection, 2-year age interval at blood collection, and sex. Respiratory allergen-specific and total IgE levels in the serum were measured using fluorescent assays. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression models stratified on sex and glioblastoma, the most common glioma subtype. Data were stratified on time from blood collection to tumor diagnosis to assess how long before glioma diagnosis the association could be observed.
RESULTS
Among women, testing positive for allergen-specific IgE (>0.35 kU(A)/L) was associated with decreased risk of glioblastoma compared with testing negative (≤0.35 kU(A)/L; OR = 0.46, 95% CI = 0.23 to 0.93). Among both sexes combined, testing positive for total IgE (>100 kU/L) was associated with decreased risk of glioma compared with testing negative (≤100 kU/L; OR = 0.75, 95% CI = 0.56 to 0.99), and simultaneously testing positive for allergen-specific IgE and total IgE was associated with a borderline statistically significantly decreased risk of glioblastoma and glioma compared with simultaneously testing negative for these types of IgE. Testing positive for total IgE at least 20 years before diagnosis was associated with decreased risk of glioma compared with testing negative (OR = 0.54, 95% CI = 0.30 to 0.99).
CONCLUSION
An inverse association between IgE levels and risk of glioma was detected; the association was present at least 20 years before tumor diagnosis.
背景
先前的巢式病例对照研究表明，过敏的预测生物标志物 IgE 与胶质瘤的风险呈负相关，但这些发现并不一致。我们的研究目的是评估这种关联，并确定在诊断为胶质瘤之前多久可以观察到这种关联。
方法
我们使用挪威扬纳斯血清库队列的血清标本进行了巢式病例对照研究。在 1974 年 1 月 1 日至 2007 年 12 月 31 日期间被诊断患有胶质瘤的献血者（594 例病例组），按采血日期、采血时 2 岁年龄间隔和性别与未患胶质瘤的献血者（1177 例对照组）进行匹配。使用荧光测定法测量血清中呼吸道过敏原特异性和总 IgE 水平。使用条件逻辑回归模型，按性别和胶质母细胞瘤分层，计算比值比（OR）和 95%置信区间（CI）。根据从采血到肿瘤诊断的时间进行分层，以评估在诊断为胶质瘤之前多久可以观察到这种关联。
结果
在女性中，与检测为阴性（≤0.35 kU(A)/L）相比，检测为过敏原特异性 IgE 阳性（>0.35 kU(A)/L）与降低胶质母细胞瘤的风险相关（OR = 0.46，95%CI = 0.23 至 0.93）。在男女混合组中，与检测为阴性（≤100 kU/L）相比，检测为总 IgE 阳性（>100 kU/L）与降低胶质瘤的风险相关（OR = 0.75，95%CI = 0.56 至 0.99），同时检测为过敏原特异性 IgE 和总 IgE 阳性与同时检测为阴性相比，与降低胶质母细胞瘤和胶质瘤的风险呈边缘统计学显著相关。与检测为阴性相比，至少在诊断前 20 年检测为总 IgE 阳性与降低胶质瘤的风险相关（OR = 0.54，95%CI = 0.30 至 0.99）。
结论
检测到 IgE 水平与胶质瘤风险之间存在负相关；这种关联在肿瘤诊断前至少 20 年就存在。
Zotero 插件